Inhibition of TRIP1/S8/hSug1, a component of the human 19S proteasome, enhances mitotic apoptosis induced by spindle poisons

Molecular Cancer Therapeutics

Volumn 5, Issue 1, 2006, Pages 29-38

  Yamada, Hiroshi Y ^a   Gorbsky, Gary J ^a  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BUB1 RELATED PROTEIN; NOCODAZOLE; PACLITAXEL; PROTEASOME; PROTEASOME INHIBITOR; SMALL INTERFERING RNA; BENZYLOXYCARBONYLLEUCYL LEUCYL LEUCINE ALDEHYDE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; BUB1 SPINDLE CHECKPOINT PROTEIN; CYSTEINE PROTEINASE INHIBITOR; LEUPEPTIN; PEPTIDE FRAGMENT; PROTEIN KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; THYROID HORMONE RECEPTOR INTERACTING PROTEIN; THYROID-HORMONE-RECEPTOR INTERACTING PROTEIN; TRANSCRIPTION FACTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBUNIT; GENE ACTIVATION; GENE TARGETING; HELA CELL; HUMAN; HUMAN CELL; MITOSIS SPINDLE; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; MITOSIS; PHYSIOLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOPTOSIS; CYSTEINE PROTEINASE INHIBITORS; HELA CELLS; HUMANS; LEUPEPTINS; MITOSIS; MITOTIC SPINDLE APPARATUS; NOCODAZOLE; PACLITAXEL; PEPTIDE FRAGMENTS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN KINASES; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS;

EID: 33644854741     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0126     Document Type: Article

References (42)

1. Bhalla KN. Microtubule-targeted anticancer agents and apoptosis. Oncogene 2003;22:9075-86.
2. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65.
3. Mollinedo F, Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 2003;8:413-50.
4. Blagosklonny MV, Fojo T. Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer 1999;83:151-6.
5. Bharadwaj R, Yu H. The spindle checkpoint, aneuploidy, and cancer. Oncogene 2004;23:2016-27.
6. Cleveland DW, Mao Y, Sullivan KF. Centromeres and kinetochores: from epigenetics to mitotic checkpoint signaling. Cell 2003;112:407-21.
7. Gorbsky GJ. The mitotic spindle checkpoint. Curr Biol 2001;11: R1001-4.
8. Weaver BA, Cleveland DW. Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell 2005;8:7-12.
9. DeLuca JG, Moree B, Hickey JM, Kilmartin JV, Salmon ED. hNuf2 inhibition blocks stable kinetochore-microtubule attachment and induces mitotic cell death in HeLa cells. J Cell Biol 2002;159:549-55.
10. Hori T, Haraguchi T, Hiraoka Y, Kimura H, Fukagawa T. Dynamic behavior of Nuf2-Hec1 complex that localizes to the centrosome and centromere and is essential for mitotic progression in vertebrate cells. J Cell Sci 2003;116:3347-62.
11. Bacus SS, Gudkov AV, Lowe M, et al. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 2001;20:147-55.
12. Deacon K, Mistry P, Chernoff J, Blank JL, Patel R. p38 Mitogen-activated protein kinase mediates cell death and p21-activated kinase mediates cell survival during chemotherapeutic drug-induced mitotic arrest. Mol Biol Cell 2003;14:2071-87.
13. Shin HJ, Baek KH, Jeon AH, et al. Dual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring of chromosomal instability. Cancer Cell 2003;4:483-97.
14. Michel L, Diaz-Rodriguez E, Narayan G, Hernando E, Murty VV, Benezra R. Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells. Proc Natl Acad Sci U S A 2004;101:4459-64.
15. Kops GJ, Foltz DR, Cleveland DW. Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc Natl Acad Sci U S A 2004;101:8699-704.
16. Zhang Y, Lees E. Identification of an overlapping binding domain on Cdc20 for Mad2 and anaphase-promoting complex: model for spindle checkpoint regulation. Mol Cell Biol 2001;21:5190-9.
17. Lee EA, Keutmann MK, Dowling ML, Harris E, Chan G, Kao GD. Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells. Mol Cancer Ther 2004;3:661-9.
18. Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001;8:739-58.
19. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004;5:417-21.
20. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59:2615-22.
21. Almond JB, Cohen JM. The proteasome: a novel target for cancer chemotherapy. Leukemia 2002;4:433-43.
22. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001;1:222-31.
23. Attaix D, Combaret L, Pouch MN, Thailander D. Regulation of proteolysis. Curr Opin Clin Nutr Metab Care 2001;4:45-9.
24. Pagano M. Cell cycle regulation by the ubiquitin pathway. FASEB J 1997;11:1067-75.
25. Hershko A. Roles of ubiquitin-mediated proteolysis in cell cycle control. Curr Opin Cell Biol 1997;9:788-99.
26. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998;67:425-79.
27. Bochtler M, Ditzel L, Groll M, Hartmann C, Huber R. The proteasome. Annu Rev Biophys Biomol Struct 1999;28:295-317.
28. Gordon C, McGurk G, Wallace M, Hastie ND. A conditional lethal mutant in the fission yeast 26S protease subunit mts3+ is defective in metaphase to anaphase transition. J Biol Chem 1996;271: 5704-11.
29. Kallio M, Weinstein J, Daum JR, Burke DJ, Gorbsky GJ. Mammalian p55CDC mediates association of the spindle checkpoint protein Mad2 with the cyclosome/anaphase-promoting complex, and is involved in regulating anaphase onset and late mitotic events. J Cell Biol 1998;141: 1393-406.
30. Martello LA, McDaid HM, Regl DL, et al. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. Clin Cancer Res 2000;6:1978-87.
31. Lee JW, Ryan F, Swaffield JC, Johnston SA, Moore DD. Interaction of thyroid-hormone receptor with a conserved transcriptional mediator. Nature 1995;374:91-4.
32. Akiyama K, Yokota K, Kagawa S, et al. cDNA cloning of a new putative ATPase subunit p45 of the human 26S proteasome, a homolog of yeast transcriptional factor Sug1p. FEBS Lett 1995;363:151-6.
33. Su K, Yang X, Roos MD, Paterson AJ, Kudlow JE. Human Sug1/p45 is involved in the proteasome-dependent degradation of Sp1. Biochem J 2000;348 Pt 2:281-9.
34. Gonzalez F, Delahodde A, Kodadek T, Johnston SA. Recruitment of a 19S proteasome subcomplex to an activated promoter. Science 2002; 296:548-50.
35. Makino Y, Yoshida T, Yogosawa S, Tanaka K, Muramatsu M, Tamura TA. Multiple mammalian proteasomal ATPases, but not proteasome itself, are associated with TATA-binding protein and a novel transcriptional activator, TIP120. Genes Cells 1999;4:529-39.
36. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Proteasome inhibition measurements: clinical application. Clin Chem 2000;46:673-83.
37. Feng Y, Longo DL, Ferris DK. Polo-like kinase interacts with proteasomes and regulates their activity. Cell Growth Differ 2001;12: 29-37.
38. Michel LS, Liberal V, Chatterjee A, et al. MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature 2001;409:355-9.
39. Zhou BB, Li H, Yuan J, Kirschner MW. Caspase-dependent activation of cyclin-dependent kinases during Fas-induced apoptosis in Jurkat cells. Proc Natl Acad Sci U S A 1998;95:6785-90.
40. Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2004;3: 59-70.
41. Teither BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999;5: 2638-45.
42. Muratani M, Tansey WP. How the ubiquitin-proteasome system controls transcription. Nat Rev Mol Cell Biol 2003;4:192-201.